Compare Cytokinetics Inc (CYTK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while iShares 20 Plus Year Treasury Bond ETF trades at $83.74. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | TLT | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | — |
52-Week High | $87.26 | $92.06 |
52-Week Low | $33.23 | $83.02 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
TLT trades at $83.97, down 0.59% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as fixed income sees renewed interest amid economic uncertainty. Recent dividend payments of $0.32-$0.34 highlight income generation, while technical indicators show oversold conditions with RSI at 27.67 suggesting potential rebound opportunity.
Long-term Treasury bonds offer attractive yields but face interest rate sensitivity. The Fed's hawkish stance presents near-term headwinds, though TLT's 4-5x higher starting yields than pre-crisis levels provide income appeal. Investors must weigh duration risk against potential Fed policy shifts and inflation trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
